Columbia Asset Management Maintains Stake in Gilead Sciences, Inc. (GILD)
Columbia Asset Management held its stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,681 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Columbia Asset Management’s holdings in Gilead Sciences were worth $260,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the stock. Weatherstone Capital Management lifted its stake in shares of Gilead Sciences by 22.1% during the 2nd quarter. Weatherstone Capital Management now owns 5,474 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 989 shares in the last quarter. Vantage Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 6.4% during the 2nd quarter. Vantage Investment Advisors LLC now owns 3,937 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 236 shares in the last quarter. Johnson Financial Group Inc. lifted its stake in shares of Gilead Sciences by 34.1% during the 2nd quarter. Johnson Financial Group Inc. now owns 46,280 shares of the biopharmaceutical company’s stock valued at $3,276,000 after buying an additional 11,768 shares in the last quarter. Skba Capital Management LLC lifted its stake in shares of Gilead Sciences by 33.7% during the 2nd quarter. Skba Capital Management LLC now owns 142,500 shares of the biopharmaceutical company’s stock valued at $10,086,000 after buying an additional 35,900 shares in the last quarter. Finally, Aberdeen Asset Management PLC UK increased its holdings in Gilead Sciences by 9.3% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 2,057,324 shares of the biopharmaceutical company’s stock worth $145,617,000 after acquiring an additional 175,102 shares during the period. Institutional investors own 74.62% of the company’s stock.
In related news, EVP Gregg H. Alton sold 50,000 shares of the stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the completion of the transaction, the executive vice president now directly owns 113,237 shares in the company, valued at approximately $8,945,723. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 666,819 shares of company stock valued at $52,303,086. Corporate insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.44 on Friday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The company has a market cap of $94,560.00, a PE ratio of 7.43, a PEG ratio of -1.19 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period last year, the company posted $2.75 EPS. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio is 23.66%.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/18/columbia-asset-management-maintains-stake-in-gilead-sciences-inc-gild.html.
GILD has been the topic of a number of analyst reports. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Thursday, August 31st. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a report on Thursday, August 31st. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price on the stock in a report on Friday, October 13th. Credit Suisse Group reaffirmed an “outperform” rating and set a $85.00 target price (up previously from $79.00) on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $84.87.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.